0 CHECKOUT

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2015

  • ID: 3500403
  • October 2015
  • 131 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • A1M Pharma AB
  • Am-Pharma B.V.
  • Cellmid Limited
  • DiaMedica Inc.
  • DURECT Corporation
  • G1 Therapeutics, Inc.
  • MORE

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2015

Summary

The report ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2015’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • A1M Pharma AB
  • Am-Pharma B.V.
  • Cellmid Limited
  • DiaMedica Inc.
  • DURECT Corporation
  • G1 Therapeutics, Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Acute Renal Failure (ARF) (Acute Kidney Injury) Overview

Therapeutics Development

Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview

Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis

Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies

Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by Universities/Institutes

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies

Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes

Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development

A1M Pharma AB

Adrenomed AG

Am-Pharma B.V.

Angion Biomedica Corp.

Bolder Biotechnology, Inc.

Cellmid Limited

Complexa, Inc.

DiaMedica Inc.

Digna Biotech, S.L.

DURECT Corporation

F. Hoffmann-La Roche Ltd.

G1 Therapeutics, Inc.

Hadasit Medical Research Services & Development Ltd

Kringle Pharma, Inc.

NephroGenex, Inc.

NeuroVive Pharmaceutical AB

Noorik Biopharmaceuticals AG

Nyken BV

Opsona Therapeutics Limited

Orion Oyj

ProMetic Life Sciences Inc.

Quark Pharmaceuticals, Inc.

STATegics, Inc.

Thrasos, Inc.

Torrent Pharmaceuticals Limited

Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

A1M-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

adrecizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BB-3 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BBT-030 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BBT-045 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CAB-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cardiotrophin-1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy to Activate Wnt7b for Kidney Injury - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CXA-10 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cyclosporine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DM-199 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DUR-928 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HYPER-IL-6 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

KP-100IT - Drug Profile

Product Description

Mechanism of Action

R&D Progress

levosimendan - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MTP-131 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

N-003 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NYK-1341 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OPN-305 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PBI-4419 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pyridoxamine dihydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

QPI-1002 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

R-190 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recombinant Human Alkaline Phosphatase - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RLS-003 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RO-6839328 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile

Product Description

Mechanism of Action

R&D Progress

STSE-15 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

THR-184 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TRC-160334 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Acute Renal Failure (ARF) (Acute Kidney Injury) - Recent Pipeline Updates

Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects

Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products

Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones

Featured News & Press Releases

Jul 07, 2015: Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury

Jun 09, 2015: Angion Biomedica To Commence Phase 2 Clinical Trial of BB3 in Acute Kidney Injury

Mar 27, 2015: NephroGenex Announces Data on Acute Kidney Injury at National Kidney Foundation 2015 Spring Clinical Meetings

Feb 23, 2015: Opsona Therapeutics Patent issued in USA covering an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof

Feb 18, 2015: Opsona Therapeutics Patent issued in US and EU covering the Opsona-developed antibody OPN-305, which is directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof

Feb 02, 2015: DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases

Jan 20, 2015: AM-Pharma starts Adaptive Phase II trial of recAP in Acute Kidney Injury

Dec 15, 2014: Complexa Initiates Phase 1B Study of CXA-10 in Acute Kidney Injury

Nov 13, 2014: AM-Pharma Presents Preclinical Data On Mode-Of-Action For RecAP In Acute Kidney Injury

Sep 16, 2014: Thrasos Announces Successful Formal Interim Analysis and Clinical Update for Phase 2 Study of THR-184 for Acute Kidney Injury

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2015

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Adrenomed AG, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma B.V., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Bolder Biotechnology, Inc., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Limited, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa, Inc., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Inc., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Digna Biotech, S.L., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corporation, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics, Inc., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma, Inc., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex, Inc., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeuroVive Pharmaceutical AB, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noorik Biopharmaceuticals AG, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Nyken BV, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Opsona Therapeutics Limited, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Orion Oyj, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ProMetic Life Sciences Inc., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals, Inc., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics, Inc., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos, Inc., H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Limited, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Recent Pipeline Updates, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2015

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Routes of Administration, H2 2015

Number of Products by Stage and Routes of Administration, H2 2015

Number of Products by Molecule Types, H2 2015

Number of Products by Stage and Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

A1M Pharma AB
Adrenomed AG
Am-Pharma B.V.
Angion Biomedica Corp.
Bolder Biotechnology, Inc.
Cellmid Limited
Complexa, Inc.
DiaMedica Inc.
Digna Biotech, S.L.
DURECT Corporation
F. Hoffmann-La Roche Ltd.
G1 Therapeutics, Inc.
Hadasit Medical Research Services & Development Ltd
Kringle Pharma, Inc.
NephroGenex, Inc.
NeuroVive Pharmaceutical AB
Noorik Biopharmaceuticals AG
Nyken BV
Opsona Therapeutics Limited
Orion Oyj
ProMetic Life Sciences Inc.
Quark Pharmaceuticals, Inc.
STATegics, Inc.
Thrasos, Inc.
Torrent Pharmaceuticals Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Novartis AG
  • Abbott Laboratories Ltd.
  • GlaxoSmithKline PLC
  • Sanofi S.A.
  • Actavis
  • Genfit